Dual SGLT1/SGLT2 Inhibitor Phlorizin Ameliorates Non-Alcoholic Fatty Liver Disease and Hepatic Glucose Production in Type 2 Diabetic Mice

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease

(2019) Yoshimasa Aso et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

No direct effect of SGLT2 activity on glucagon secretion

(2019) Rune E. Kuhre et al.   DIABETOLOGIA

The liver as an endocrine organ - linking NAFLD and insulin resistance

(2019) Matthew J Watt et al.   ENDOCRINE REVIEWS

Development of SGLT1 and SGLT2 inhibitors

(2018) Timo Rieg et al.   DIABETOLOGIA

Diabetes induces tri-methylation at lysine 9 of histone 3 at Slc2a4 gene in skeletal muscle: A new target to improve glycemic control

(2018) Caio Y. Yonamine et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Animal models for analyzing metabolic syndrome-associated liver diseases

(2017) Koichi Tsuneyama et al.   PATHOLOGY INTERNATIONAL

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long–Evans Tokushima fatty rats

(2016) Norihisa Nishimura et al.   JOURNAL OF GASTROENTEROLOGY

Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory

(2016) Caio Yogi Yonamine et al.   Nutrition & Metabolism

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

Sodium alginate prevents progression of non-alcoholic steatohepatitis and liver carcinogenesis in obese and diabetic mice

(2016) Tsuneyuki Miyazaki et al.   Oncotarget

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction

(2016) Chikara Komiya et al.   PLoS One

High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice

(2015) Roel A van der Heijden et al.   Aging-US

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

(2015) Yuka Hayashizaki-Someya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

SH2 domain-containing inositol 5-phosphatase (SHIP2) inhibition ameliorates high glucose-induced de-novo lipogenesis and VLDL production through regulating AMPK/mTOR/SREBP1 pathway and ROS production in HepG2 cells

(2015) Sattar Gorgani-Firuzjaee et al.   FREE RADICAL BIOLOGY AND MEDICINE

The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice

(2015) Takayasu Ideta et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

(2015) Caroline Bonner et al.   NATURE MEDICINE

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

(2015) Shirong Qiang et al.   Diabetology & Metabolic Syndrome

GLUT2, glucose sensing and glucose homeostasis

(2014) Bernard Thorens   DIABETOLOGIA

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

A Dietary Restriction Influences the Progression But Not the Initiation of MSG-Induced Nonalcoholic Steatohepatitis

(2014) Makoto Fujimoto et al.   JOURNAL OF MEDICINAL FOOD

Hepatocyte nuclear factors 1α/4α and forkhead box A2 regulate the solute carrier 2A2 (Slc2a2) gene expression in the liver and kidney of diabetic rats

(2013) Aline David-Silva et al.   LIFE SCIENCES

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

(2011) R. A. DeFronzo et al.   DIABETES OBESITY & METABOLISM

Clinical Review of Nonalcoholic Steatohepatitis in Liver Surgery and Transplantation

(2010) Amit D. Tevar et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS

Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice

(2009) Yu Yamazaki et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Adaptive  -Cell Proliferation Is Severely Restricted With Advanced Age

(2009) M. M. Rankin et al.   DIABETES

Dose dependent development of diabetes mellitus and non-alcoholic steatohepatitis in monosodium glutamate-induced obese mice

(2009) Yoshiyuki Sasaki et al.   LIFE SCIENCES

SLC2A2 gene expression in kidney of diabetic rats is regulated by HNF-1α and HNF-3β

(2009) H.S. Freitas et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Glucokinase and molecular aspects of liver glycogen metabolism

(2008) Loranne Agius   BIOCHEMICAL JOURNAL

Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia

(2008) Yuko Nakanishi et al.   JOURNAL OF AUTOIMMUNITY